Physician profile
Kathleen Meyer
NPI 1477675775
$3,680.24
in general payments reported to CMS, 2019-2025
22 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $801 · 2023: $1,053 · 2024: $1,371 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.16 |
| Education | $266.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $579.82 | 2021-2025 | |
| Janssen Biotech, INC. | $571.68 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $422.36 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $341.36 | 2022-2024 | Ilumya |
| Abbvie INC. | $207.29 | 2022-2024 | |
| Amgen INC. | $201.29 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $200.04 | 2022-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $193.79 | 2022-2025 | Cabtreo, Jublia, Arazlo |
| Leo Pharma INC. | $172.89 | 2021-2025 | Adbry |
| Incyte Corporation | $123.11 | 2022-2024 | Opzelura |
| Ucb, INC. | $113.53 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $108.23 | 2023-2024 | |
| Galderma Laboratories, L.P. | $86.37 | 2024 | Aklief |
| Epi Health, LLC | $78.00 | 2022 | |
| Mayne Pharma Commercial LLC | $65.70 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $64.81 | 2022-2023 | Klisyri |
| Fidia Pharma USA INC. | $47.18 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $27.60 | 2022-2023 | |
| Dermavant Sciences, INC. | $25.98 | 2022-2023 | Vtama |
| Boston Scientific Corporation | $17.32 | 2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.62 | 2024 | Spevigo |
| Pfizer INC. | $15.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.